Paratek Pharma

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI) and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Paratek has Special Protocol Assessment agreements with the FDA for the phase 3 trials planned in ABSSSI and CABP.

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $13.2 Million in the First Quarter 2021; 6% Increase Over the Fourth Quarter 2020 -- BARDA has Initiated the First Procurement of NUZYRA Valued at ~$38 Million in the Second Quarter of 2021 -- NUZYRA Expansion into the Primary Care Setting Underway

Paratek Pharmaceuticals Announces First Quarter 2021 Total Revenue of $16.4 Million and Initiation of First BARDA Procurement

Paratek's new broad-spectrum antibiotic Nuzyra has shown good uptake so far in the hospital setting, and the company is starting to try to break into primary care as well.

Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business

Paratek (PRTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Paratek (PRTK) Moves 14.5% Higher: Will This Strength Last?

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2020 Results - Earnings Call Transcript

Paratek (PRTK) delivered earnings and revenue surprises of -712.50% and -59.53%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Misses Revenue Estimates

-- NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020 -- NUZYRA Expansion into the Primary Care Setting in 2021

Paratek Pharmaceuticals Announces Full Year 2020 Total Revenue of $46.9 Million including NUZYRA® (omadacycline) Net U.S. Sales of $38.8 Million

BOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at the 10th Annual SVB Leerink Global Healthcare Conference which will be held Thursday, February 25, 2021 at 11:20 a.m. ET.

Paratek Pharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference

BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Wednesday, February 24, 2021 at 4:30 p.m. EST to report its financial results for the quarter and full year ended December 31, 2020 and provide a corporate update. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial: 877-407-0792 and international investors should dial: 201-689-8263. The conference ID is 13716761. Investors can also access the call at http://public.viavid.com/index.php?id=143647. About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The Company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights. Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC (Almirall). Paratek retains the development and commercialization rights for sarecycline in the rest of the world. In 2019, Paratek was awarded a contract from BARDA, valued at ~$285 million, to support the development and U.S.-based manufacturing of NUZYRA for the treatment of pulmonary anthrax. For more information, visit www.ParatekPharma.com or follow @ParatekPharma on Twitter. About NUZYRA® NUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains. Please see full Prescribing Information for NUZYRA at www.NUZYRA.com . Forward Looking Statements This press release contains forward-looking statements including statements related to our overall strategy, products, prospects and potential. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2019 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

argenx

EyePoint Pharmaceuticals

Gilead Sciences

Gracell Biotechnologies

Inovio Pharmaceuticals

Eli Lilly

Zai Lab Ltd.

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments.

Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs

Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc. Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc.

Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC Group

Bausch Health Companies Inc

Chiasma

The Bruce Fund, co-managed by founder Robert Bruce (Trades, Portfolio) and his son Jeff, revealed in November that its top trades included a new position in Chiasma Inc. (NASDAQ:CHMA), position boosts in Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) and Bausch Health Companies Inc. (NYSE:BHC) and reductions in its Apple Inc. (NASDAQ:AAPL) and NextEra Energy Inc. (NYSE:NEE) holdings.

The Bruce Fund's Top 5 3rd-Quarter Trades

Nuzyra launch trajectory is top of class compared with other antibiotics. BARDA deal signed late 2019 is worth $285M.

Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale

BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at the 2020 Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 11:25 a.m. ET or 4:25 p.m. GMT.

Paratek Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q3 2020 Results - Earnings Call Transcript

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Paratek Pharmaceuticals (PRTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BOSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. EST to report its financial results for the quarter ended September 30, 2020 and provide a corporate update.

Paratek Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020

Key Highlights Include Data on NUZYRA as an Alternative to Standard of Care to Reduce Clostridioides Difficile Infections and Real-World Experience with NUZYRA for Nontuberculous Mycobacterial and MDR/XDR Gram Negative Infections Key Highlights Include Data on NUZYRA as an Alternative to Standard of Care to Reduce Clostridioides Difficile Infections and Real-World Experience with NUZYRA for Nontuberculous Mycobacterial and MDR/XDR Gram Negative Infections

Paratek Pharmaceuticals Presenting New Data on NUZYRA® (Omadacycline) at IDWeek 2020

Paratek Pharmaceuticals: Undervalued Antibiotics Play With A Fighting Chance

BOSTON, Sept.  09, 2020  (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at H.C. Wainwright 22nd Annual Global Investment Conference, Monday, September 14, 2020 at 5:00 p.m. ET.

Paratek Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Paratek Pharmaceuticals, Inc.(PRTK) CEO Evan Loh on Q2 2020 Results - Earnings Call Transcript

Paratek (PRTK) delivered earnings and revenue surprises of -278.57% and -72.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Lags Revenue Estimates

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose 2.3% in pre-market trading after the company reported Q2 results.

Recap: Paratek Pharmaceuticals Q2 Earnings

BOSTON, Aug.  05, 2020  (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at two upcoming healthcare conferences. 

Paratek Pharmaceuticals to Present at Two August 2020 Healthcare Conferences

BOSTON, July  28, 2020  (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 8:30 a.m. EDT to report its financial results for the quarter ended June 30, 2020 and provide a corporate update.

News for Paratek Pharma Stock (PRTK)